Julian Harrison
Stock Analyst at BTIG
(2.28)
# 2,728
Out of 4,981 analysts
43
Total ratings
45.95%
Success rate
-0.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MAZE Maze Therapeutics | Maintains: Buy | $30 → $37 | $23.25 | +59.14% | 3 | Sep 12, 2025 | |
| CGEM Cullinan Therapeutics | Reiterates: Buy | $32 | $6.35 | +403.94% | 1 | Sep 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Buy | $112 | $85.87 | +30.43% | 2 | Sep 9, 2025 | |
| TBPH Theravance Biopharma | Maintains: Buy | $24 → $25 | $14.40 | +73.61% | 2 | Jun 27, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $10.14 | +294.48% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $9.79 | +329.01% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $15.55 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $20.16 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $1.05 | +757.14% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $1.84 | +334.78% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.31 | +2,512.67% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $61 | $18.01 | +238.70% | 3 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $7.47 | +100.80% | 2 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $25 | $26.77 | -6.61% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $58.38 | -12.64% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $14.84 | +169.54% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $36.86 | +16.66% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $2.92 | +36.99% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $1.75 | +8,471.43% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $53.27 | -32.42% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $403.11 | - | 2 | Feb 11, 2022 |
Maze Therapeutics
Sep 12, 2025
Maintains: Buy
Price Target: $30 → $37
Current: $23.25
Upside: +59.14%
Cullinan Therapeutics
Sep 10, 2025
Reiterates: Buy
Price Target: $32
Current: $6.35
Upside: +403.94%
ABIVAX Société Anonyme
Sep 9, 2025
Reiterates: Buy
Price Target: $112
Current: $85.87
Upside: +30.43%
Theravance Biopharma
Jun 27, 2025
Maintains: Buy
Price Target: $24 → $25
Current: $14.40
Upside: +73.61%
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $10.14
Upside: +294.48%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $9.79
Upside: +329.01%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $15.55
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $20.16
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $1.05
Upside: +757.14%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $1.84
Upside: +334.78%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.31
Upside: +2,512.67%
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $18.01
Upside: +238.70%
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $7.47
Upside: +100.80%
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $26.77
Upside: -6.61%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $58.38
Upside: -12.64%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $14.84
Upside: +169.54%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $36.86
Upside: +16.66%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $2.92
Upside: +36.99%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $1.75
Upside: +8,471.43%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $53.27
Upside: -32.42%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $403.11
Upside: -